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Comparative eﬀ ectiveness of MRI in breast cancer (COMICE) 
trial: a randomised controlled trial
Lindsay Turnbull, Sarah Brown, Ian Harvey, Catherine Olivier, Phil Drew, Vicky Napp, Andrew Hanby, Julia Brown 
Summary
Background MRI might improve diagnosis of breast cancer, reducing rates of reoperation. We assessed the clinical 
eﬃ  cacy of contrast-enhanced MRI in women with primary breast cancer.
Methods We undertook an open, parallel group trial in 45 UK centres, with 1623 women aged 18 years or older with 
biopsy-proven primary breast cancer who were scheduled for wide local excision after triple assessment. Patients 
were randomly assigned to receive either MRI (n=816) or no further imaging (807), with use of a minimisation 
algorithm incorporating a random element. The primary endpoint was the proportion of patients undergoing a repeat 
operation or further mastectomy within 6 months of random assignment, or a pathologically avoidable mastectomy 
at initial operation. Analysis was by intention to treat. This study is registered, ISRCTN number 57474502.
Findings 816 patients were randomly assigned to MRI and 807 to no MRI. Addition of MRI to conventional triple 
assessment was not signiﬁ cantly associated with reduced a reoperation rate, with 153 (19%) needing reoperation in 
the MRI group versus 156 (19%) in the no MRI group, (odds ratio 0·96, 95% CI 0·75–1·24; p=0·77). 
Interpretation Our ﬁ ndings are of beneﬁ t to the NHS because they show that MRI might be unnecessary in this 
population of patients to reduce repeat operation rates, and could assist in improved use of NHS services. 
Funding National Institute for Health Research’s Health Technology Assessment Programme.
Introduction
The quality-assurance standard for the UK National 
Health Service Breast Screening Programme (NHS BSP)1 
has set a target for reoperation rates for incomplete 
tumour excision of less than 10%. In 2001, when the 
COMICE protocol was written, the actual rate was 14·2% 
and has not reduced over time. According to the 2006–07 
UK audit of screen-detected breast cancers,2 17% of 
patients with primary breast cancer with a diagnosis of 
deﬁ nite malignant disease (C5 or B5) underwent 
reoperation for positive tumour margins.2 
In studies of surgery3,4 without subsequent 
radiotherapy for treatment of primary breast cancer, 
researchers reported a 25–40% risk of local tumour 
recurrence when the initial disease was multifocal or 
multicentric, compared with 11% for more than one 
malignant focus. An increased rate of inadequate or 
indeterminate resection margins in specimens with 
more than one malignant foci could account for these 
ﬁ ndings, but detailed sectioning of mastectomy 
specimens revealed that additional tumour foci were 
present in 30–63% of women who were mammo-
graphically suspected of having unifocal disease.5 When 
tumour resection margins are clear and radiotherapy is 
administered, rates of recurrence for unifocal and 
multifocal tumours are similar.6,7 
Malignant lesions are diﬃ  cult to detect in the 
mammographically dense breast. Substantial evidence 
exists for a good relation between MRI and histology of 
resected specimens, with results exceeding those for 
X-ray mammography or ultrasound.8–10 Findings from 
two observational studies11,12 of the role of dynamic 
contrast-enhanced MRI in clinical management of 
patients scheduled for breast-conservation surgery have 
shown management to be altered in 14–18% of patients 
because of detection of disease that was more extensive 
than was ﬁ rst diagnosed, although neither study reported 
factors predictive of alteration in outcome. 
Cost-eﬀ ectiveness of MRI in this clinical setting is 
unknown. In 2001, we started the COmparative 
eﬀ ectiveness of MR Imaging in breast CancEr (COMICE) 
trial  to assess the clinical eﬃ  cacy and cost-eﬀ ectiveness 
of contrast-enhanced MRI in women with primary breast 
cancer who were scheduled for wide local excision. In 
this trial, we address the uncertainty about preoperative 
identiﬁ cation of multicentric disease, the eﬀ ect of MRI 
on clinical management, quality of life measures, and 
patient satisfaction, and incorporated a health economic 
assessment.
Here we report results of the primary endpoint of the 
trial, the proportion of patients undergoing a repeat 
operation or further mastectomy within 6 months of 
randomisation, or a pathologically avoidable mastectomy 
at initial operation, and provide data about quality of life 
and health economic assessments.13
Methods
Patients
COMICE is a multicentre, randomised, controlled, 
open-label, parallel group trial, designed to compare the 
eﬃ  cacy of MRI and standard triple assessment with 
triple assessment alone in reduction of reoperation rates. 
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Triple assessment was deﬁ ned as clinical, radiological 
(X-ray mammography and ultrasound) and pathological 
(ﬁ ne-needle aspiration cytology or core biopsy) 
assessment. The study was undertaken at 45 UK centres. 
We chose an approach to trial design that would enable 
results to be generalisable to clinical practice. Women 
aged 18 years or older with biopsy-proven primary breast 
cancer who were scheduled for wide local excision after 
triple assessment were eligible. Exclusion criteria 
included patients who: were medically unstable; had 
known contraindications to MRI; had allergic reactions 
to paramagnetic contrast agent or severe allergic 
diathesis; were on renal dialysis; had undergone 
chemotherapy or hormonal therapy for cancer for the 
contralateral breast in previous 12 months, or had 
chemotherapy planned to any site before breast surgery; 
had previous surgery or radiotherapy for cancer to the 
ipsilateral breast or previous surgery to the ipsilateral 
breast within the past 4 months for benign breast disease; 
had a history of serious breast trauma within the past 
3 months; were pregnant or breastfeeding; or had a 
disability preventing MRI in a prone position. Patients 
scheduled for wide local excision on the basis of triple 
assessment were invited to participate in the study by the 
consultant breast surgeons or consultant radiologist 
during discussions about treatment options. Further 
information was provided by the research nurse, and, 
whenever possible, patients were given at least 24 h to 
consider participation. 
All patients provided written informed consent. The 
trial was approved by multicentre and local research 
ethics committees. An independent Data Monitoring 
and Ethics Committee (DMEC) was used to ensure 
safety issues and ethical considerations were 
appropriately addressed.
Randomisation and masking
Patients were randomised to receive either MRI or no 
further imaging (no MRI) on a 1:1 basis, with a 
minimisation algorithm incorporating a random 
element. Minimisation factors were the consultant 
breast surgeon, age (<50 vs ≥50 years), and breast 
density group1 (American College of Radiology Breast 
Imaging—Reporting and Data Systems [ACR BI-RADS 
type 1] vs group 2 ACR BI-RADS type 2, 3, or 4). 
Randomisation was administered by the University of 
Leeds Clinical Trials Research Unit’s automated 24-hour 
telephone randomisation system, by either the research 
nurse or the consultant breast surgeon.
Procedures
X-ray mammography and ultrasound were undertaken 
according to standard local protocol. We used a standard 
protocol for MRI, which was done on 1.5T systems 
(GE Healthcare, London UK; Siemens AG, Berlin, 
Germany; and Philips Healthcare, Amsterdam, the 
Netherlands) with dedicated bilateral breast-surface coils 
for signal reception, with a few scans done at 1.0T. 
Multiple thin-slice (in-plane resolution 1·3×0·8 mm, slice 
thickness 4 mm) fast-gradient echo sequences (temporal 
resolution 45 s) were acquired coronally through both 
breasts for up to 450 s to measure the pattern of contrast 
uptake. The ﬁ rst two datasets were obtained before and 
the remainder after an intravenous bolus injection of 
Gadolinium-based contrast agent was given (0·1 mmol 
Gd- diethyl enetriaminepenta-acetic acid per kg of body-
weight). High resolution (0·7 mm×0·4 mm in-plane, slice 
thickness 2·5 mm) post-contrast, fat-suppressed three 
dimensional MR images were obtained coronally for 
morphological information.
We classiﬁ ed lesions according to the pattern of the 
time-signal intensity curve and morphological 
appearance.14–16 Details of the MRI protocol and method 
of analysis can be obtained from the HTA monologue.13 
816 in intention-to-treat population
761 received MRI
53 no MRI interpreted
11 MRI technical failures
10 cases of MRI not available before 
surgery
9 refused MRI
5 did not attend MRI appointment
5 patients had MRI but results not used
5 not suitable for MRI
3 MRI scans abandoned, patients 
claustrophobia
2 MRI results uninterpretable
2 randomised after surgery
1 staﬃng issues 
2 unable to identify whether MRI received
(data unavailable at time of analysis) 
816 analysed (primary endpoint)* 807 analysed (primary endpoint)* 
3871 excluded 
1360 did not meet inclusion criteria 
1173 refused to participate 
1338 excluded for other reasons 
5496 assessed for eligibility 
1625 randomised 
817 assigned to receive triple assessment plus  
MRI (MRI) 
808 assigned to triple assessment alone (no MRI) 
807 in intention-to-treat population 
798 did not receive MRI 
9 received MRI 
6 on patient request 
3 on clinician request 
4 lost to follow-up 
1 patient withdrew from 
follow-up before surgery
3 primary endpoint (data 
unavailable at time of 
analysis)
1 conﬁrmation of consent  
not received  
1 conﬁrmation of consent  
not received 
6 lost to follow-up 
2 patients moved away
4 primary endpoint (data 
unavailable at time of 
analysis)
Figure 1: Trial proﬁ le 
*Patients lost to follow-up regarded as not having a primary endpoint event.
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Patients allocated to no MRI were scheduled to 
undergo wide local excision as planned. If the ﬁ ndings 
for those undergoing MRI were not equivalent to those 
of triple assessment, results were reviewed by a 
multidisciplinary team. MR-guided biopsy sampling 
(either at locality or regional centre) or, if unavailable, 
MR-localised, ultrasound-guided ﬁ ne-needle aspiration 
cytology or core biopsy was needed for multi centric 
lesions that were 5 mm or larger, and was recommended 
for multifocal lesions in cases that were diagnostic-
ally diﬃ  cult. 
Surgery was planned as appropriate, with any changes 
in management recorded. Clear margins were assumed 
to be free of both ductal carcinoma in situ and invasive 
tumour. Every participating consultant breast surgeon 
provided their local deﬁ nition of a clear margin before 
starting recruitment. Local deﬁ nitions were applied to 
both trial groups, and ranged from 0·5–5·0 mm for 
invasive disease and 1·0–10·0 mm for ductal carcinoma 
in situ.
Histopathological assessment of excised specimens 
was done at every participating centre in accordance with 
guidelines in the NHS BSP publication—pathology 
reporting in breast cancer screening.17 These core 
guidelines contain the minimum dataset for breast 
cancer histopathology reports, and were deﬁ ned by the 
Royal College of Pathologists. 
We gathered clinical follow-up data at 6 and 12 months 
after surgery, then yearly thereafter, until all patients 
had been followed up for at least 1 year. We undertook a 
quality assurance process to ensure that MRI scans 
were completed in accordance with the technical needs 
of the trial protocol, and that scan interpretation was 
consistent between all participating centres. This 
process was completed by an independent radiologist, 
who was masked to the original MRI ﬁ ndings. 
Full details of the quality assurance protocol are in the 
HTA monologue.13
Outcome measures
The primary clinical outcome was the proportion of 
patients undergoing a repeat operation—either further 
wide local excision or mastectomy within 6 months of 
random assignment, or a pathologically avoidable 
mastectomy at initial operation (termed reoperation rate). 
Imaging ﬁ ndings from patients undergoing a mastectomy 
at initial operation were reviewed every 12 months in 
conjunction with histopathological ﬁ ndings by the DMEC 
to identify any false-positive MR ﬁ ndings that could lead 
to a pathologically avoidable mastectomy. The deﬁ nition 
of a pathologically avoidable mastectomy that was 
speciﬁ ed by the independent DMEC and agreed by the 
Trial Steering Committee was as follows: MRI-detected 
multifocal lesions resulting in mastectomy, but 
histopathology showing only localised malignant disease; 
or, the size of the index lesion, as measured by MRI, 
being larger than that detected by triple assessment 
alone, resulting in mastectomy, but histopathology 
showing that either the size of the index lesion or the size 
of the index lesion and ductal carcinoma in situ was 
30 mm or less in diameter. 
We also undertook an economic assessment according 
to the NHS cost perspective (ie, actual cost of care 
delivered to patients) and quantiﬁ ed health-related quality 
of life, as assessed by the Euro quality of life 5D 
questionnaire (EQ-5D),18,19 to investigate the cost-
eﬀ ectiveness of MRI in this setting. This assessment 
formed the primary health economic endpoint. Secondary 
endpoints were change in clinical management, quality 
of life as assessed by the functional assessment of cancer 
therapy (breast cancer version; FACT-B)20,21 at 8 weeks 
after randomisation and 6 and 12 months after initial 
surgery, local tumour recurrence, and the eﬀ ectiveness 
of the imaging techniques.
MRI (n=816) No MRI (n=807) Total (n=1623)
Number of patients recruited by surgeon undertaking randomisation
Fewer than 10 115 (14%) 115 (14%) 230 (14%)
10 or more 701 (86%) 692 (86%) 1393 (86%)
Age at randomisation
Younger than age 50 years 187 (23%) 187 (23%) 374 (23%)
50 years or older 629 (77%) 620 (77%) 1249 (77%)
Median (IQR) 57 (50–63) 57 (50–64) 57 (50–64)
Breast density at randomisation
ACR BI-RADS group 1 (type 1) 102 (13%) 106 (13%) 208 (13%)
ACR BI-RADS group 2 (type 2, 3, or 4) 714 (88%) 701 (87%) 1415 (87%)
Menopausal status
Premenopausal 232 (28%) 234 (29%) 466 (29%)
Postmenopausal 574 (70%) 565 (70%) 1139 (70%)
Missing data 10 (1%) 8 (1%) 18 (1%)
Contraceptive pill or slow-release injection use
Current (at randomisation) 23 (3%) 28 (4%) 51 (3%)
Previously 458 (56%) 478 (59%) 936 (58%)
Never 327 (40%) 294 (36%) 621 (38%)
Missing data 8 (1%) 7 (<1%) 15 (<1%)
HRT use
Current (at randomisation) 63 (8%) 46 (6%) 109 (7%)
Previously 232 (28%) 231 (29%) 463 (29%)
Never 514 (63%) 528 (65%) 1042 (64%)
Missing data 7 (<1%) 2 (<1%) 9 (<1%)
Type of surgery
Wide local excision 750 (92%) 787 (98%) 1537 (94%)
Mastectomy 58 (7%) 10 (1%) 68 (4%)
Quadrantectomy and mini ﬂ ap 1 (<1%) 0 (0%) 1 (<1%)
Other 2 (<1%) 0 (0%) 2 (<1%)
Did not have surgery 2 (<1%) 2 (<2%) 4 (<2%)
Lost to follow-up 1 (<1%) 1 (<1%) 2 (<1%)
Missing data 2 (<1%) 7 (<1%) 9 (<1%)
Data are n (%) unless otherwise stated. HRT=hormone replacement therapy. ACR BI-RADS=American College of 
Radiology Breast Imaging Reporting and Data System.
Table 1: Baseline characteristics
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Statistical analysis
With an assumption that the addition of MRI would 
reduce the overall primary-endpoint rate from about 15%4 
to 10%, we needed 1840 patients to detect this reduction 
with 90% power at a 5% (two-sided) signiﬁ cance level, 
with a χ2 test without continuity correction. Conventional 
minimum 80% power is associated with a widely accepted 
level of risk for large-scale clinical trials. The COMICE 
trial was powered at 90% because we believed this power 
was achievable; however, were 80% power chosen, we 
would have needed 1372 patients. 
We compared the reoperation rate between groups with 
use of logistic regression, adjusting for the minimisation 
factors. Patients undergoing a mastectomy at initial 
operation because of patient decision alone were regarded 
as having a reoperation. Those who were lost to follow-up 
were classiﬁ ed as not having a primary-endpoint event. 
We undertook prespeciﬁ ed exploratory subgroup analyses 
to assess the interaction of tumour type (lobular carcinoma 
vs all other types) with MRI and ad-hoc exploratory 
analyses to assess the interaction of age with MRI.
Eﬀ ectiveness of imaging examined the agreement 
between predicted patient management established from 
results of MRI compared with management based on 
results of histopathological assessement of the excised 
specimen. Predicted patient management was based on 
raw data and calculated with special reference to: number 
and type (benign or malignant) of lesions detected; 
maximum diameter of all foci of invasive or in-situ 
carcinoma, or the sum of invasive and in-situ carcinoma 
present; and location and extent of additional tumours 
(localised, multifocal, or multicentric). DMEC deﬁ nitions 
(pre-established criteria) were used to establish whether 
a change in surgical management from wide local 
excision to mastectomy was needed on the basis of results 
from both MRI and histopathology separately. With an 
assumption that histopathology was the gold standard, 
and regarding mastectomy to be a positive outcome and 
wide local excision to be negative, we calculated sensitivity, 
speciﬁ city, and positive and negative predictive values for 
the predicted management. In further exploratory 
analyses, we examined the extent of agreement (linear-
weighted κ) in size of tumour between histopathology 
and the imaging techniques. 
We summarised quality of life data with a timeframe 
of plus or minus 14 days around the expected date of 
completion of the 8-week questionnaire, plus or minus 
28 days for the 6-month questionnaire, and 56 days for 
the 12-month questionnaire. We calculated health-related 
quality of life, as measured by the EQ-5D, and resource 
costs for every patient, and compared the groups with 
regression analyses, adjusting for age, body-mass index, 
baseline health-related quality of life, and cancer 
recurrence. All hypothesis tests were two-sided and 
undertaken at the 5% signiﬁ cance level. Analysis was by 
intention to treat. All statistical analyses were undertaken 
with SAS version 9.1.
MRI (n=816) No MRI (n=807) Total (n=1623)
Weight of specimen (g) from wide local excision
Median (IQR) 54·0 (35·0–90·0) 51·0 (33·0–77·0) 52·8 (34·0–83·4)
Missing data 55/750 (7%) 62/787 (8%) 117/1537 (8%)
Invasive carcinoma
Total 743 (91%) 723 (90%) 1466 (90%)
Tumour type
Mucinous carcinoma 20 (3%) 13 (2%) 33 (2%)
Tubular carcinoma 24 (3%) 28 (4%) 52 (4%)
Ductal non-speciﬁ ed tumour 570 (77%) 544 (75%) 1114 (76%)
Lobular carcinoma 63 (9%) 70 (10%) 133 (9%)
Not assessable 2 (<1%) 1 (<1%) 3 (<1%)
Mixed 8 (1%) 15 (2%) 23 (2%)
Other 54 (7%) 52 (7·2%) 106 (7%)
Missing data 2 (<1%) 0 (0%) 2 (<1%)
Grade
I 177 (24%) 179 (25%) 356 (24%)
II 358 (48%) 331 (46%) 689 (47%)
III 200 (27%) 205 (28%) 405 (28%)
Missing data 8 (1%) 8 (1%) 16 (1%)
Extent of disease
Localised 613 (83%) 631 (87%) 1244 (85%)
Multifocal 90 (12%) 72 (10%) 162 (11%)
Not assessable 11 (2%) 5 (<1%) 16 (1%)
Multicentric 11 ( 2%) 6 (<1%) 17 (1%)
Missing data 18 (2%) 9 (1%) 27 (2%)
Size of index lesion (mm)
Median (IQR) 15·0 (11·0–21·5) 15·0 (11·0–21·0) 15·0 (11·0–21·0)
Missing data 12/743 (2%) 11/723 (2%) 23/1466 (2%)
Size of invasive plus DCIS (mm)
Median (IQR) 18 (14–26) 18 (13–25) 18 (13–26)
Missing 127/743 (17%) 112/723 (15%) 239/1466 (16%)
Invasive tumour
Margin status for invasive tumour
Reaches margin 99 (13%) 106 (15%) 205 (14%)
Uncertain 17 (2%) 26 (4%) 43 (3%)
Does not reach margin 620 (83%) 582 (81%) 1202 (82%)
Missing data 7 (1%) 9 (1%) 16 (1%)
Distance of invasive tumour to margin (mm)
Median (IQR) 4·0 (1·0–6·0) 4·0 (1·0–6·0) 4·0 (1·0–6·0)
Missing data 53/743 (7%) 57/723 (8%) 110/1466 (8%)
DCIS
Marginal status for DCIS
Reaches margin 94 (16%) 83 (15%) 177 (15%)
Uncertain 19 (3%) 18 (3%) 37 (3%)
Does not reach margin 333 (57%) 347 (61%) 680 (9%)
Missing data 140/586 (24%) 120/568 (21%) 260/1154 (23%)
Distance of DCIS to margin (mm)
Median (IQR) 3·0 (1·0–7·0) 3·0 (1·0–6·0) 3·0 (1·0–6·0)
Missing data 206/586 (35%) 193/568 (34%) 399/1154 (35%)
Data are median (IQR), n/N (%), or n (%). DCIS=ductal carcinoma in situ. 
Table 2: First operation pathology details
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Role of the funding source
The sponsors of this study commissioned this research, 
but had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The 
authors had full access to all study data and were 
responsible for the decision to submit for publication. 
Results
The randomisation phone line was made live in 
December, 2001, but the ﬁ rst patient was not randomly 
assigned until Feb 20, 2002. The last patient was 
randomly assigned on Jan 31, 2007. 1623 patients were 
randomly assigned (816 in the MRI group and 807 in the 
no MRI group) to the COMICE trial by 107 consultant 
breast surgeons and radiologists from 45 UK centres. 
Although the achieved sample size was smaller than 
was the sample size of 1840 patients needed for 90% 
power, this number still provides the study with 
86% power to detect a diﬀ erence of 5% in reoperation 
rates. 1393 patients (86%) were recruited by consultant 
breast surgeons who recruited at least ten patients. 
Figure 1 shows the study protocol.22  
Table 1 shows the baseline characteristics of patients. 
Characteristics were well balanced between the groups. 
Most patients were 50 years or older, had breast density 
group 2 (2, 3, or 4 on the ACR BI-RADS scale), were 
postmenopausal, and had been identiﬁ ed through the 
NHS Breast Screening Programme (n=847, 52%). The 
proportion of premenopausal to postmenopausal women 
was consistent with the expected age distribution of 
breast cancer. Median time from randomisation to MRI 
for patients assigned to receive MRI was 3 days (IQR 1–6), 
and from randomisation to initial surgery was 14 days 
(8–20) in this group and 13 days (8–18) in the group with 
no further imaging. For those undergoing a mastectomy 
in the MRI group, the median time from randomisation 
to surgery was 19 days (12–34), consisting of a median of 
22 days (10–47) for those undergoing an additional biopsy 
before surgery and a median of 17 days (7–25) for those 
proceeding directly to mastectomy. An interval of 243 days 
between randomisation and surgery was recorded for 
one patient who underwent neoadjuvant chemotherapy. 
The protocol speciﬁ ed that an MRI scan should not delay 
surgery; therefore, only 2% of patients waited longer than 
40 days between random assignment and surgery, and 
less than 1% more than 50 days.
Table 2 shows pathology results for the initial 
operation. The median weight of wide local excision 
specimens, the size and extent of tumour, and the 
percentage of excision margins associated with either 
invasive cancer or ductal carcinoma in situ were similar 
between groups. 153 MRI scans (19%) were reread as 
part of the quality-assurance process, including all 
recruiting centres. 12 scans (8%) were technically 
non-compliant with the scanning protocol, and we 
regarded ﬁ ve (3%) as misreported (three of which arose 
from non-compliant scans). 12 of the non-compliant 
scans were from six centres, all with low recruitment. 
Combined, these centres accounted for only 43 (5%) of 
the total number of MRI scans undertaken within the 
trial. The remaining two misreported scans were from 
two centres with high recruitment, accounting for 
31 (4%) of the total MRI scans. As such, no sensitivity 
analyses were deemed necessary.
309 patients (19%) underwent either a repeat operation 
or mastectomy at further operation within 6 months of 
randomisation, or a pathologically avoidable mastectomy 
at initial surgery, with a diﬀ erence between the MRI 
and no MRI group of 0·58% (95% CI –3·24 to 4·40%). 
No signiﬁ cant diﬀ erence in reoperation rates was 
identiﬁ ed between the groups (odds ratio [OR] 0·96, 
0·75 to 1·24, p=0·77). For the minimisation factors, 
neither breast density (p=0·51) nor surgeon (p=0·34) 
were identiﬁ ed to be signiﬁ cantly associated with 
reoperation rates. Patients aged 50 years or older, 
however, were reported to be less likely to undergo a 
reoperation (as previously deﬁ ned) than were those 
younger than 50 years (OR 0·64, 0·47–0·86, p=0·0029). 
We undertook multilevel modelling to further 
investigate surgeon eﬀ ect, but no such eﬀ ect was 
identiﬁ ed (p=0·12) when surgeon was classed as a 
random eﬀ ect.
Table 3 shows a breakdown of initial and further 
surgery. 16 patients in the MRI group (2%) underwent a 
pathologically avoidable mastectomy at initial surgery, 
as did two patients in the no MRI group (<1%) who had 
MRI (n=816) No MRI (n=807) Total (n=1623)
Initial operation
Wide local excision 750 (92%) 787 (98%) 1537 (95%)
Mastectomy 58 (7%) 10 (1%) 68 (4%)
Other 3 (<1%) 0 3 (<1%)
Did not undergo initial surgery 2 (<1%) 2 (<1%) 4 (<1%)
Lost to follow-up or missing data 3 (<1%) 8 (1%) 11 (<1%)
Repeat operations within 6 months
Further wide local excision 85 (10%) 90 (11%) 175 (11%)
Mastectomy 48 (6%) 61 (8%) 109 (7%)
Other 1 (<1%) 1 (<1%) 2 (<1%)
Pathologically avoidable initial 
mastectomy or patient choice
19 (2%) 4 (<1%) 23 (1%)
Did not undergo further surgery 659 (81%) 645 (80%) 1304 (80%)
Lost to follow-up 4 (<1%) 6 (<1%) 10 (<1%)
Table 3: Initial and repeat operations
Histopathology Total
Wide local excision Mastectomy
MRI
WLE 458 (84%) (true negative) 89 (16%) (false negative) 547
Mastectomy 55 (38%) (false positive) 89 (62%) (true positive) 144
Total 513 178 691
Table 4: MRI-predicted patient management
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an MRI. 39 patients (5%) in the MRI group correctly 
underwent a mastectomy as a result of MRI ﬁ ndings, 
and a further three patients underwent a mastectomy on 
the basis of patient decision alone. When taking into 
account only those patients who underwent a repeat 
operation, the median time from randomisation to this 
operation was 41 days (32–56 days).
Additionally, 13 patients (2%) underwent previously 
unplanned surgery to the contralateral breast at initial 
operation because of additional ﬁ ndings that were 
identiﬁ ed by MRI (12 patients underwent wide local 
excision and one chose to have a mastectomy). 27 patients 
had a biopsy sample taken from the contralateral breast 
on the basis of MRI ﬁ ndings.
A change in clinical management that was attributable 
to MRI ﬁ ndings was proposed for 55 patients (7%) in 
the MRI group, and an additional three patients chose 
to have a mastectomy. A change in management was 
made for 50 of 55 patients (91%) because additional 
disease was identiﬁ ed by MRI. Of these patients, 
MRI No MRI
n Median (IQR) Mean (SD) 95% CI n Median (IQR) Mean (SD) 95% CI
Baseline
FACT-B total 613 114·0 (100·5–123·0) 110·4 (17·6) 109·0–111·8 613 114·0 (100·0–123·8) 110·3 (16·9) 109·0–111·7
FACT-G total 624 88·0 (77·3–95·0) 84·6 (13·6) 83·5–85·6 619 88·0 (75·8–95·0) 84·7 (12·9) 83·6–85·7
FACT-B physical wellbeing 640 25·7 (23·0–27·0) 24·6 (3·5) 24·3–24·8 632 25·8 (23·0–27·0) 24·7 (3·2) 24·4–24·9
FACT-B social and family 
wellbeing
637 26·0 (24·0–28·0) 24·8 (4·2) 24·4–25·1 631 26·0 (23·0–28·0) 24·5 (4·4) 24·2–24·9
FACT-B emotional wellbeing 635 14·0 (10·0–16·0) 12·9 (4·6) 12·5–13·2 626 14·0 (10·0–17·0) 13·1 (4·6) 12·7–13·4
FACT-B functional wellbeing 640 24·0 (20·0–27·0) 22·3 (5·4) 21·9–22·7 629 24·0 (19·0–27·0) 22·4 (5·1) 22·0–22·8
FACT-B additional concerns 634 26·0 (22·0–30·0) 25·8 (5·7) 25·3–26·2 626 26·0 (22·0–30·0) 25·7 (5·5) 25·2–26·1
Trial outcome index 624 75·0 (66·0–81·9) 72·7 (12·3) 71·7–73·7 619 74·0 (66·0–82·0) 72·7 (11·5) 71·8–73·6
8 weeks after randomisation
FACT-B total 421 112·0 (93·0–123·0) 107·2 (20·7) 105·3–109·2 412 111·0 (95·6–123·0) 107·4 (20·4) 105·4–109·3
FACT-G total 420 86·0 (71·8–94·1) 82·3 (15·6) 80·8–83·8 412 85·3 (73·0–94·3) 82·2 (15·4) 80·7–83·7
FACT-B physical wellbeing 423 24·0 (20·0–26·0) 22·1 (5·1) 21·6–22·6 417 24·0 (20·0–26·0) 22·4 (4·7) 21·9–22·8
FACT-B social and family 
wellbeing
426 26·0 (23·3–28·0) 24·6 (4·5) 24·2–25·1 416 26·0 (22·2–28·0) 24·2 (4·7) 23·7–24·7
FACT-B emotional wellbeing 425 16·0 (13·0–18·0) 15·1 (4·0) 14·7–15·5 416 16·0 (13·0–18·0) 15·1 (4·2) 14·6–15·5
FACT-B functional wellbeing 428 22·0 (16·5–25·0) 20·5 (6·0) 19·9–21·1 416 22·0 (17·0–25·0) 20·5 (6·0) 20·0–21·1
FACT-B additional concerns 429 26·0 (21·0–30·0) 24·9 (6·6) 24·3–25·5 418 26·0 (21·0–30·0) 25·2 (6·4) 24·6–25·8
Trial outcome index 422 70·0 (57·5–80·0) 67·5 (15·4) 66·1–69·0 415 71·0 (59·0–80·0) 68·1 (14·9) 66·7–69·5
6 months after initial surgery
Fact-B total 545 112·0 (92·0–126·0) 107·2 (22·2) 105·3–109·1 533 111·0 (92·3–125·0) 107·2 (21·8) 105·4–109·1
FACT-G total 549 87·0 (71·0–96·0) 82·5 (16·4) 81·1–83·9 535 86·0 (73·0–96·0) 82·4 (16·3) 81·0–83·8
FACT-B physical wellbeing 559 24·0 (19·0–26·0) 22·3 (5·3) 21·9–22·7 541 24·0 (19·8–26·0) 22·1 (5·2) 21·7–22·6
FACT-B social/family 
wellbeing
559 25·0 (21·0–28·0) 23·7 (4·8) 23·3–24·1 540 25·7 (21·0–28·0) 23·7 (4·9) 23·3–24·2
FACT-B emotional wellbeing 553 16·0 (14·0–18·0) 15·5 (3·9) 15·2–15·9 541 16·3 (13·0–18·0) 15·4 (4·0) 15·1–15·8
FACT-B functional wellbeing 554 23·0 (17·0–26·0) 21·0 (6·2) 20·5–21·5 542 22·0 (17·0–26·0) 21·1 (6·0) 20·6–21·6
FACT-B additional concerns 556 26·0 (20·0–30·0) 24·7 (7·0) 24·1–25·3 543 26·0 (21·0–30·0) 24·8 (6·7) 24·2–25·3
Trial outcome index 547 72·0 (57·0–82·0) 67·9 (16·5) 66·5–69·3 535 71·0 (58·0–81·0) 68·1 (15·8) 66·7–69·4
1 year after initial surgery
FACT-B total 583 115·8 (96·0–126·0) 109·9 (21·0) 108·2–111·6 569 115·0 (98·0–127·0) 110·6 (20·3) 109·0–112·3
FACT-G total 586 88·9 (75·0–97·0) 84·3 (15·8) 83·0–85·5 575 89·0 (76–98·0) 84·7 (15·8) 83·5–86·0
FACT-B physical wellbeing 601 25·0 (22·0–27·0) 23·5 (4·6) 23·1–23·8 583 25·0 (22·0–27·0) 23·6 (4·3) 23·3–24·0
FACT-B social/family 
wellbeing
605 25·7 (21·0–28·0) 23·6 (5·1) 23·2–24·0 582 25·7 (21·0–28·0) 23·5 (5·4) 23·0–23·9
FACT-B emotional wellbeing 595 16·0 (13·0–18·0) 15·3 (3·9) 15·0–15·6 583 16·0 (14·0–18·0) 15·5 (3·9) 15·2–15·8
FACT-B functional wellbeing 604 23·6 (18·0–27·0) 21·9 (5·8) 21·4–22·3 587 24·0 (19·0–27·0) 22·1 (5·6) 21·6–22·5
FACT-B additional concerns 609 27·0 (21·4–31·0) 25·7 (6·5) 25·1–26·2 583 27·0 (22·0–30·0) 25·8 (6·0) 25·3–26·3
Trial outcome index 590 75·3 (61·2–82·0) 71·1 (14·9) 69·9–72·3 576 75·0 (63·0–82·0) 71·6 (13·9) 70·4–72·7
FACT-B=functional assessment of cancer therapy-breast. FACT-G=functional assessment of cancer therapy-general
Table 5: Quality of life summaries for patients who completed questionnaires within set timeframes
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15 (30%) underwent a pathologically avoidable 
mastectomy as deﬁ ned by the DMEC, with the other 
35 patients correctly managed. For the remaining ﬁ ve 
patients, a change in management was proposed 
because of extensive microcalciﬁ cations secondary to 
ductal carcinoma in situ (identiﬁ ed on review of 
mammography and ultrasound; three patients), primary 
lung malignancy detected on MRI (one patient), and 
the reason was missing for one patient. Of the 58 patients 
who underwent a mastectomy, 32 had an additional 
biopsy, 11 did not have a biopsy, and data were unavailable 
for the remaining 15 patients. Of the 16 patients who 
underwent an avoidable mastectomy, three did and six 
did not have a biopsy, and data are missing for the 
remaining seven patients.
For predicted patient management, agreement of 
results from histopathology with imaging ﬁ ndings was 
considered for patients assigned to have an MR scan on 
the basis of the deﬁ nitions used by DMEC for the 
appropriateness of the chosen surgical procedure. 
According to histopathological ﬁ ndings, predicted 
management for 561 patients (69%) in the MRI group 
was wide local excision, for 196 patients (24%) was 
mastectomy, and predicted management was not 
established for 59 patients (7%). Of the 757 patients for 
whom histopathologically predicted management was 
established, predicted management according to 
MRI could not be established for 66 patients (9%), 
resulting in 691 with predicted management assessable 
via both modalities. 
Table 4 shows MRI-predicted patient management. 
MRI correctly predicted wide local excision for 
458 of 547 patients (84%). For 89 of 547 patients (16%), 
MRI predicted a need for wide local excision, although 
histopathology ﬁ ndings suggested that they should have 
undergone a mastectomy. 89 of 144 (62%) who were 
predicted by MRI to need a mastectomy were also 
identiﬁ ed to need such management from results of 
histopathology, and 55 (38%) were identiﬁ ed by 
histopathology as needing only wide local excision. 
Sensitivity was 50·0% (95% CI 42·7–57·4) and speciﬁ city 
89·3% (86·6–92·0%). 
Agreement in the staging of tumours between MRI 
and histopathology showed that all imaging modalities 
oﬀ er, at most, only some agreement with pathology, 
when taking into account the size of index lesion alone 
(κ values; ultrasound 0·46, 95% CI 0·41–0.50, X-ray 
mammography 0·45, 0·41–0·49], MRI 0·45, 0·39–0·50). 
However, when incorporating data from patients with 
ductal carcinoma in situ, agreement with ultrasound was 
poorer, with the 95% CIs around the weighted κ statistic 
almost entirely excluding those for MRI (κ values; 
ultrasound 0·38, 0·34–0·42, X-ray mammography 0·41, 
0·37–0·46, MRI 0·48, 0·42–0·53). 
We undertook multilevel modelling to investigate 
whether there was a radiologist eﬀ ect on the size of lesion 
and the extent of disease as identiﬁ ed by MRI, compared 
with histopathological results. We identiﬁ ed that a 
signiﬁ cant radiologist eﬀ ect (p=0·0186) was related to 
the size of lesion; however, the variation in data was 
attributable to diﬀ erences between patients rather than 
to radiologists. No radiologist eﬀ ect was reported to be 
associated with diﬀ erences in extent of disease.
In relation to reoperation rate, we identiﬁ ed no 
statistically signiﬁ cant interaction between tumour type 
(lobular carcinoma vs all other types) and the addition of 
MRI to triple assessment (χ2 0·13, p=0·72), or age and 
the addition of MRI to triple assessment (χ2 0·16, p=0·69). 
Patients with lobular carcinoma were more likely to 
undergo reoperation (OR 0·52, 0·30–0·92, p=0·0242), 
compared with patients who did not have lobular 
carcinoma. However, we interpreted our results with 
caution because of the low number of patients with 
lobular carcinoma (9%).
Table 5 shows the quality-of-life results at every time 
point for patients who completed their quality-of-life 
questionnaire within the relevant timeframes. Overall, 
quality-of-life scores were similar between the two 
treatment groups, decreasing slightly between baseline 
and 8 weeks after randomisation, then recovering 
between 6 and 12 months after initial surgery. 
In our economic assessment at 12 months after surgery, 
we identiﬁ ed no statistically signiﬁ cant diﬀ erence in 
health-related quality of life, as measured by the EQ-5D, 
between the two groups (p=0·075). Results of this 
assessment suggested that  a cost diﬀ erence between the 
two trial groups might exist, with the MRI strategy having 
a larger mean resource cost per patient than the no MRI 
strategy (£5508·40 [US$8877·36] vs £5213·50 [$8402·10]), 
although the diﬀ erence was not signiﬁ cant (p=0·075). 
Full details of this assessment are provided elsewhere.13
Discussion
Our results show that addition of MRI to conventional 
triple assessment has no beneﬁ t on reduction of 
reoperation rate. Of 1623 patients, about 11% of all 
patients underwent a further wide local excision, 7% 
underwent a mastectomy at further operation, and 1% 
underwent a pathologically avoidable mastectomy or a 
mastectomy by choice at initial operation. The overall 
reoperation rate (19%) was slightly higher than the NHS 
Breast Screening Programme rate of 10% in 2006–07, 
although our ﬁ ndings are within the 13–21% range 
quoted in 2006–07 for the UK.2
We incorporated the rate of pathologically avoidable 
mastectomy at initial operation into the primary endpoint 
because MRI might have overestimated the size and 
extent of disease, thus resulting in an avoidable 
recommendation for mastectomy. In the MRI group, 7% 
of patients underwent a mastectomy at initial operation, 
and of these, 16 patients (2% of all MRI patients) had a 
pathologically avoidable mastectomy, and less than 1% of 
all MRI patients chose to have a mastectomy. Because we 
analysed only data for women who were identiﬁ ed via 
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triple assessment and already scheduled to receive wide 
local excision, we cannot compare the rate of pathologically 
avoidable mastectomy as a consequence of triple 
assessment alone with that for MRI. 
These results emphasise the need to take biopsy 
samples of all lesions that might result in an alteration to 
the planned surgical procedure. However, we emphasise 
that 5% of patients correctly underwent a mastectomy at 
initial operation and 2% underwent contralateral breast 
surgery for undetected malignancy as a result of MRI 
ﬁ ndings. Nonetheless, MRI did not result in a signiﬁ cant 
reduction in the rate of repeat operation or mastectomy 
at further operation in the MRI group.
The COMICE study is the ﬁ rst large pragmatic 
prospective, multicentre trial to investigate the eﬀ ective-
ness of MRI for detection of small breast lesions that are 
suitable for wide local excision. The 95% CI and p value 
associated with the OR for undergoing reoperation in the 
MRI group was highly non-signiﬁ cant, showing that the 
results would be highly unlikely to diﬀ er had the target 
sample size of 1840 patients been attained.23 
Our results are similar to those of a systematic review 
and meta-analysis24 of non-randomised studies of MRI 
in preoperative breast assessment. In this meta-analysis, 
researchers emphasised that MRI investigation of the 
aﬀ ected breast in women newly diagnosed with breast 
cancer could increase the rate of potentially unnecessary 
surgery. They showed that MRI detected additional 
multifocal and multicentric disease in the aﬀ ected breast 
in 16% of cases. The summary estimate of the positive 
predictive value was 66·0% (95% CI, 52–77) and the 
conversion rate from wide local excision to mastectomy 
was 8·1% (5·9–11·3). 1% of patients underwent a 
pathologically avoidable mastectomy secondary to MRI. 
Our results lend support to these ﬁ ndings, thus 
reiterating that outcomes of the COMICE trial can be 
generalised to clinical practice. Houssami and Hayes25 
undertook a meta-analysis of 12 observational studies 
that examined the detection capability and eﬀ ect of 
preoperative MRI on newly diagnosed, early breast 
cancer treatment. They reported that MRI changed 
surgical management, generally from breast conservation 
to more radical surgery, but identiﬁ ed no evidence that 
MRI improved surgical treatment or outcomes. This 
ﬁ nding could be a consequence of the mode of 
presentation of imaging data to the surgeon. Complete 
excision of tumour depends on the ability of the surgeon 
to palpate the lesion in its entirety. This procedure is 
very demanding because: all imaging modalities acquire 
information with the patient in a diﬀ erent position to 
that assumed during surgery; palpation of tumour might 
be diﬃ  cult, dependent on the composition of the breast 
and the characteristics of the cancer; and, if wire 
localisation is used, in which typically only one wire is 
inserted, the tumour margin could be inadequately 
delineated. Techniques to ensure surgical precision is at 
an optimum need further examination.
Extent of experience of the radiologists is acknowledged 
as a potential limitation of our study, but this issue will 
always exist in real practice. Although analysis of our 
data showed a signiﬁ cant radiologist eﬀ ect, the variation 
in data was probably attributable to diﬀ erences between 
patients rather than between radiologists. Notwith-
standing, eﬀ orts continue in protocol development to 
improve the speciﬁ city of breast MRI. 
Our economic analysis was consistent with the clinical 
ﬁ ndings. In the analysis, we identiﬁ ed no diﬀ erence in 
health-related quality of life between groups 12 months 
after initial surgery. However, in terms of total costs, 
results suggested a diﬀ erence between the two trial 
groups, with the MRI group costing more than the no 
MRI group, although the diﬀ erence was not statistically 
signiﬁ cant. In view of the similar clinical and health-
related quality-of-life outcomes of patients in both groups, 
we conclude that the addition of MRI to the conventional 
triple assessment might result in extra use of resources 
at the initial surgery period, with few or no beneﬁ ts to 
saving resources or health outcomes, and the additional 
burden on patients to attend extra hospital visits.
Our results have important implications in routine 
clinical practice for the appropriate use of health-service 
resources and patient burden on health services. MRI is 
an expensive procedure. Because surgical use of MR data 
to direct wide local excision is similar worldwide, we 
believe that our ﬁ ndings are generalisable to all health-
care providers, and show that MRI might not be necessary 
in this population of patients in terms of reduction of 
reoperation rates. 
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